Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:52 am
| PEG Ratio | -2.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Tata Chemicals Ltd operates within the chemicals sector, specifically focusing on inorganic products such as caustic soda and soda ash. The company’s revenue trajectory has shown fluctuations in recent quarters, with reported sales of ₹4,239 Cr in September 2022, declining to ₹3,998 Cr by September 2023. The most recent quarter, December 2023, recorded sales of ₹3,730 Cr, indicating a downward trend. Annual sales for FY 2023 were reported at ₹16,789 Cr, while TTM sales stood at ₹14,695 Cr for FY 2025. This decline in revenue is concerning, particularly against a backdrop of increasing expenses, which were ₹12,969 Cr for FY 2023 and ₹12,748 Cr TTM for FY 2025. The company’s ability to navigate these challenges will be critical for maintaining its market position in a competitive landscape.
Profitability and Efficiency Metrics
Profitability metrics for Tata Chemicals reveal a concerning trend, as operating profit margins (OPM) have decreased from 23% in FY 2023 to 13% in FY 2025. The company reported an operating profit of ₹3,820 Cr for FY 2023, which fell to ₹1,953 Cr for FY 2025. Net profit has also been volatile, with a reported figure of ₹2,434 Cr in FY 2023 declining to ₹387 Cr in FY 2025. The return on equity (ROE) has stagnated at 1.20%, while return on capital employed (ROCE) stood at 3.96%. These figures are significantly lower than typical sector averages, indicating potential inefficiencies. The interest coverage ratio of 3.87 times suggests that while the company can meet its interest obligations, the declining profitability may limit future investment in growth or innovation.
Balance Sheet Strength and Financial Ratios
Tata Chemicals’ balance sheet shows a mix of strength and vulnerability. The company has total borrowings of ₹7,495 Cr against reserves of ₹22,103 Cr, indicating a relatively healthy reserve-to-borrowing ratio. However, the total liabilities have risen to ₹37,750 Cr, which is concerning given the declining profitability. The current ratio is reported at 1.09, suggesting adequate liquidity to cover short-term liabilities, but the quick ratio of 0.67 raises concerns about immediate liquidity. The price-to-book value ratio stands at 1.02x, indicating that the stock is trading close to its book value, which may not reflect strong future growth potential. Moreover, the debt-to-equity ratio of 0.29 suggests that the company is not overly leveraged, yet the declining return on assets (ROA) of 0.62% signifies underutilization of assets in generating returns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Tata Chemicals reflects a diverse ownership structure. Promoters hold 37.98%, while domestic institutional investors (DIIs) own 22.17%. Foreign institutional investors (FIIs) account for 13.73%, with the public holding 26.07%. The number of shareholders has decreased slightly to 6,50,693, indicating some erosion of investor confidence amidst declining financial performance. The stability of promoter holdings is a positive sign, but the fluctuating FIIs and DIIs suggest mixed sentiments regarding the company’s future prospects. Furthermore, the dividend payout ratio has reached 162.55% in FY 2025, highlighting a commitment to returning value to shareholders despite lower net profits. This could attract long-term investors looking for dividends but might raise concerns about the sustainability of such payouts in the face of declining earnings.
Outlook, Risks, and Final Insight
Tata Chemicals faces several risks that may impact its future performance. The declining revenue and profitability metrics pose significant challenges, particularly in a competitive chemicals market. Additionally, rising costs could further squeeze margins, while the company’s ability to manage its debt amidst lower profitability remains a concern. On the other hand, the company’s strong reserves provide a buffer against immediate financial distress and may allow for strategic investments in innovation or efficiency improvements. If Tata Chemicals can leverage its reserves effectively and reverse the current downward trends in sales and profitability, it may regain investor confidence and stabilize its market position. Conversely, continued declines may prompt a reassessment of its business model or strategic direction, necessitating prompt action to enhance operational efficiencies and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 32.9 Cr. | 71.5 | 74.8/37.5 | 3,290 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 96.3 Cr. | 15.0 | 28.4/14.7 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,494 Cr. | 476 | 751/467 | 23,295 | 759 | 3.32 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 5,046 Cr. | 549 | 779/511 | 8.86 | 378 | 2.19 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 19,236 Cr. | 755 | 1,027/742 | 59.0 | 877 | 1.46 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 7,094.50 Cr | 380.92 | 5,338.65 | 389.00 | 1.21% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,239 | 4,148 | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 | 3,877 |
| Expenses | 3,319 | 3,317 | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 | 3,340 |
| Operating Profit | 920 | 831 | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 | 537 |
| OPM % | 22% | 20% | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% | 14% |
| Other Income | 102 | 30 | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 | 128 |
| Interest | 86 | 107 | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 | 144 |
| Depreciation | 218 | 227 | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 | 285 |
| Profit before tax | 718 | 527 | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 | 236 |
| Tax % | 5% | 19% | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% | 35% |
| Net Profit | 680 | 425 | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 | 154 |
| EPS in Rs | 24.65 | 15.35 | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 | 3.02 |
Last Updated: January 1, 2026, 7:04 pm
Below is a detailed analysis of the quarterly data for Tata Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 3,877.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,719.00 Cr. (Jun 2025) to 3,877.00 Cr., marking an increase of 158.00 Cr..
- For Expenses, as of Sep 2025, the value is 3,340.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,070.00 Cr. (Jun 2025) to 3,340.00 Cr., marking an increase of 270.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 537.00 Cr.. The value appears to be declining and may need further review. It has decreased from 649.00 Cr. (Jun 2025) to 537.00 Cr., marking a decrease of 112.00 Cr..
- For OPM %, as of Sep 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Jun 2025) to 14.00%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 138.00 Cr. (Jun 2025) to 128.00 Cr., marking a decrease of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 144.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 147.00 Cr. (Jun 2025) to 144.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 285.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 280.00 Cr. (Jun 2025) to 285.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 236.00 Cr.. The value appears to be declining and may need further review. It has decreased from 360.00 Cr. (Jun 2025) to 236.00 Cr., marking a decrease of 124.00 Cr..
- For Tax %, as of Sep 2025, the value is 35.00%. The value appears to be increasing, which may not be favorable. It has increased from 12.00% (Jun 2025) to 35.00%, marking an increase of 23.00%.
- For Net Profit, as of Sep 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 316.00 Cr. (Jun 2025) to 154.00 Cr., marking a decrease of 162.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.02. The value appears to be declining and may need further review. It has decreased from 9.89 (Jun 2025) to 3.02, marking a decrease of 6.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,885 | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,695 |
| Expenses | 15,200 | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 | 12,748 |
| Operating Profit | 686 | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 | 1,947 |
| OPM % | 4% | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 13% |
| Other Income | -154 | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 | 285 |
| Interest | 579 | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 576 |
| Depreciation | 471 | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,138 |
| Profit before tax | -519 | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 | 518 |
| Tax % | 56% | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% | |
| Net Profit | -811 | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | 400 |
| EPS in Rs | -40.50 | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 | 8.63 |
| Dividend Payout % | -25% | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 198.89% | 25.44% | 22.66% | 118.96% | -48.67% | 421.12% | -93.97% | 222.25% | 73.24% | -82.13% | -11.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | -173.45% | -2.77% | 96.30% | -167.63% | 469.79% | -515.09% | 316.22% | -149.01% | -155.37% | 71.09% |
Tata Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -48% |
| 3 Years: | -40% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 25% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 4:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:14 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,311 | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 | 22,103 |
| Borrowings | 8,393 | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 | 7,495 |
| Other Liabilities | 6,127 | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 | 9,002 |
| Total Liabilities | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
| Fixed Assets | 11,007 | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 | 20,171 |
| CWIP | 468 | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 | 2,099 |
| Investments | 441 | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 | 9,555 |
| Other Assets | 8,171 | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 | 7,030 |
| Total Assets | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
Below is a detailed analysis of the balance sheet data for Tata Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 255.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 255.00 Cr..
- For Reserves, as of Sep 2025, the value is 22,103.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,339.00 Cr. (Mar 2025) to 22,103.00 Cr., marking an increase of 764.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,495.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7,072.00 Cr. (Mar 2025) to 7,495.00 Cr., marking an increase of 423.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 9,002.00 Cr.. The value appears to be improving (decreasing). It has decreased from 9,084.00 Cr. (Mar 2025) to 9,002.00 Cr., marking a decrease of 82.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 38,855.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 20,171.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,600.00 Cr. (Mar 2025) to 20,171.00 Cr., marking an increase of 571.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,099.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,913.00 Cr. (Mar 2025) to 2,099.00 Cr., marking an increase of 186.00 Cr..
- For Investments, as of Sep 2025, the value is 9,555.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,144.00 Cr. (Mar 2025) to 9,555.00 Cr., marking an increase of 411.00 Cr..
- For Other Assets, as of Sep 2025, the value is 7,030.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,093.00 Cr. (Mar 2025) to 7,030.00 Cr., marking a decrease of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 38,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
Notably, the Reserves (22,103.00 Cr.) exceed the Borrowings (7,495.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 678.00 | -7.00 | -7.00 | -5.00 | -3.00 | -5.00 | -6.00 | -5.00 | -5.00 | -3.00 | -3.00 | -6.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 |
| Inventory Days | 96 | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 |
| Days Payable | 119 | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 |
| Cash Conversion Cycle | 52 | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 |
| Working Capital Days | 11 | -4 | 31 | -4 | 27 | -2 | -102 | 27 | -29 | 29 | -22 | -21 |
| ROCE % | 3% | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Flexicap Fund | 3,750,000 | 0.53 | 300.15 | N/A | N/A | N/A |
| ICICI Prudential India Opportunities Fund | 2,879,270 | 0.68 | 230.46 | N/A | N/A | N/A |
| ICICI Prudential Value Fund | 2,843,828 | 0.38 | 227.62 | 2,792,806 | 2025-12-15 00:52:54 | 1.83% |
| ICICI Prudential Multicap Fund | 2,584,831 | 1.28 | 206.89 | N/A | N/A | N/A |
| ICICI Prudential Smallcap Fund | 2,320,406 | 2.2 | 185.73 | 2,300,000 | 2025-12-15 00:52:54 | 0.89% |
| Kotak Large & Midcap Fund | 2,064,884 | 0.55 | 165.27 | N/A | N/A | N/A |
| ICICI Prudential Multi Asset Fund | 1,137,376 | 0.12 | 91.04 | N/A | N/A | N/A |
| Tata Ethical Fund | 652,838 | 1.39 | 52.25 | N/A | N/A | N/A |
| ICICI Prudential Dividend Yield Equity Fund | 625,881 | 0.79 | 50.1 | N/A | N/A | N/A |
| Tata Mid Cap Fund | 615,450 | 0.91 | 49.26 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Diluted EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Cash EPS (Rs.) | 53.18 | 52.82 | 130.43 | 77.91 | 45.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Revenue From Operations / Share (Rs.) | 583.80 | 604.75 | 658.39 | 495.33 | 400.27 |
| PBDIT / Share (Rs.) | 85.41 | 122.86 | 158.43 | 100.49 | 68.09 |
| PBIT / Share (Rs.) | 41.37 | 84.43 | 123.45 | 68.85 | 38.29 |
| PBT / Share (Rs.) | 14.39 | 29.88 | 107.45 | 56.53 | 23.87 |
| Net Profit / Share (Rs.) | 9.14 | 14.39 | 95.45 | 46.27 | 16.11 |
| NP After MI And SOA / Share (Rs.) | 9.21 | 10.51 | 90.86 | 49.35 | 10.06 |
| PBDIT Margin (%) | 14.63 | 20.31 | 24.06 | 20.28 | 17.01 |
| PBIT Margin (%) | 7.08 | 13.96 | 18.75 | 13.90 | 9.56 |
| PBT Margin (%) | 2.46 | 4.94 | 16.32 | 11.41 | 5.96 |
| Net Profit Margin (%) | 1.56 | 2.37 | 14.49 | 9.34 | 4.02 |
| NP After MI And SOA Margin (%) | 1.57 | 1.73 | 13.80 | 9.96 | 2.51 |
| Return on Networth / Equity (%) | 1.08 | 1.20 | 11.74 | 6.88 | 1.79 |
| Return on Capital Employeed (%) | 3.33 | 7.01 | 10.43 | 6.55 | 4.08 |
| Return On Assets (%) | 0.62 | 0.72 | 6.60 | 3.71 | 0.90 |
| Long Term Debt / Equity (X) | 0.19 | 0.13 | 0.28 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.29 | 0.22 | 0.30 | 0.37 | 0.38 |
| Asset Turnover Ratio (%) | 0.39 | 0.42 | 0.48 | 0.40 | 0.14 |
| Current Ratio (X) | 1.09 | 1.05 | 1.66 | 1.23 | 1.49 |
| Quick Ratio (X) | 0.67 | 0.63 | 1.15 | 0.90 | 1.11 |
| Inventory Turnover Ratio (X) | 1.01 | 1.07 | 1.22 | 1.22 | 0.50 |
| Dividend Payout Ratio (NP) (%) | 162.55 | 166.41 | 13.72 | 20.25 | 109.30 |
| Dividend Payout Ratio (CP) (%) | 28.12 | 35.73 | 9.90 | 12.34 | 27.59 |
| Earning Retention Ratio (%) | -62.55 | -66.41 | 86.28 | 79.75 | -9.30 |
| Cash Earning Retention Ratio (%) | 71.88 | 64.27 | 90.10 | 87.66 | 72.41 |
| Interest Coverage Ratio (X) | 3.87 | 5.91 | 9.95 | 8.46 | 4.72 |
| Interest Coverage Ratio (Post Tax) (X) | 1.58 | 3.34 | 7.04 | 4.91 | 2.12 |
| Enterprise Value (Cr.) | 28656.05 | 32847.30 | 31130.10 | 31228.96 | 24062.00 |
| EV / Net Operating Revenue (X) | 1.92 | 2.13 | 1.85 | 2.47 | 2.36 |
| EV / EBITDA (X) | 13.16 | 10.48 | 7.71 | 12.20 | 13.87 |
| MarketCap / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| Retention Ratios (%) | -62.55 | -66.41 | 86.27 | 79.74 | -9.30 |
| Price / BV (X) | 1.02 | 1.24 | 1.26 | 1.36 | 1.34 |
| Price / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| EarningsYield | 0.01 | 0.01 | 0.09 | 0.05 | 0.01 |
After reviewing the key financial ratios for Tata Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.18. This value is within the healthy range. It has increased from 52.82 (Mar 24) to 53.18, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 583.80. It has decreased from 604.75 (Mar 24) to 583.80, marking a decrease of 20.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 85.41. This value is within the healthy range. It has decreased from 122.86 (Mar 24) to 85.41, marking a decrease of 37.45.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.37. This value is within the healthy range. It has decreased from 84.43 (Mar 24) to 41.37, marking a decrease of 43.06.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.39. This value is within the healthy range. It has decreased from 29.88 (Mar 24) to 14.39, marking a decrease of 15.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.14. This value is within the healthy range. It has decreased from 14.39 (Mar 24) to 9.14, marking a decrease of 5.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.21. This value is within the healthy range. It has decreased from 10.51 (Mar 24) to 9.21, marking a decrease of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 20.31 (Mar 24) to 14.63, marking a decrease of 5.68.
- For PBIT Margin (%), as of Mar 25, the value is 7.08. This value is below the healthy minimum of 10. It has decreased from 13.96 (Mar 24) to 7.08, marking a decrease of 6.88.
- For PBT Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 10. It has decreased from 4.94 (Mar 24) to 2.46, marking a decrease of 2.48.
- For Net Profit Margin (%), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 5. It has decreased from 2.37 (Mar 24) to 1.56, marking a decrease of 0.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 8. It has decreased from 1.73 (Mar 24) to 1.57, marking a decrease of 0.16.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 15. It has decreased from 1.20 (Mar 24) to 1.08, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 7.01 (Mar 24) to 3.33, marking a decrease of 3.68.
- For Return On Assets (%), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.62, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.22 (Mar 24) to 0.29, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.42 (Mar 24) to 0.39, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 1.5. It has increased from 1.05 (Mar 24) to 1.09, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.07 (Mar 24) to 1.01, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 162.55. This value exceeds the healthy maximum of 50. It has decreased from 166.41 (Mar 24) to 162.55, marking a decrease of 3.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.12. This value is within the healthy range. It has decreased from 35.73 (Mar 24) to 28.12, marking a decrease of 7.61.
- For Earning Retention Ratio (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 40. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.88. This value exceeds the healthy maximum of 70. It has increased from 64.27 (Mar 24) to 71.88, marking an increase of 7.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.87. This value is within the healthy range. It has decreased from 5.91 (Mar 24) to 3.87, marking a decrease of 2.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 3.34 (Mar 24) to 1.58, marking a decrease of 1.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,656.05. It has decreased from 32,847.30 (Mar 24) to 28,656.05, marking a decrease of 4,191.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.13 (Mar 24) to 1.92, marking a decrease of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 13.16. This value is within the healthy range. It has increased from 10.48 (Mar 24) to 13.16, marking an increase of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For Retention Ratios (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 30. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.02, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Tata Chemicals Ltd:
- Net Profit Margin: 1.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.33% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.08% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 59 (Industry average Stock P/E: 5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Bombay House, 24, Homi Mody Street, Mumbai Maharashtra 400001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Padmanabhan | Chairman |
| Mr. R Mukundan | Managing Director & CEO |
| Mr. Modan Saha | Director |
| Mrs. Padmini Khare Kaicker | Independent Director |
| Mr. Rajiv Dube | Independent Director |
| Dr. C V Natraj | Independent Director |
| Mr. K B S Anand | Independent Director |
FAQ
What is the intrinsic value of Tata Chemicals Ltd?
Tata Chemicals Ltd's intrinsic value (as of 18 January 2026) is ₹355.58 which is 52.90% lower the current market price of ₹755.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹19,236 Cr. market cap, FY2025-2026 high/low of ₹1,027/742, reserves of ₹22,103 Cr, and liabilities of ₹38,855 Cr.
What is the Market Cap of Tata Chemicals Ltd?
The Market Cap of Tata Chemicals Ltd is 19,236 Cr..
What is the current Stock Price of Tata Chemicals Ltd as on 18 January 2026?
The current stock price of Tata Chemicals Ltd as on 18 January 2026 is ₹755.
What is the High / Low of Tata Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Tata Chemicals Ltd stocks is ₹1,027/742.
What is the Stock P/E of Tata Chemicals Ltd?
The Stock P/E of Tata Chemicals Ltd is 59.0.
What is the Book Value of Tata Chemicals Ltd?
The Book Value of Tata Chemicals Ltd is 877.
What is the Dividend Yield of Tata Chemicals Ltd?
The Dividend Yield of Tata Chemicals Ltd is 1.46 %.
What is the ROCE of Tata Chemicals Ltd?
The ROCE of Tata Chemicals Ltd is 3.96 %.
What is the ROE of Tata Chemicals Ltd?
The ROE of Tata Chemicals Ltd is 1.20 %.
What is the Face Value of Tata Chemicals Ltd?
The Face Value of Tata Chemicals Ltd is 10.0.